Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul;61(1):7-16.
doi: 10.1007/s12020-018-1588-2. Epub 2018 Apr 24.

Glucocorticoid-induced osteoporosis: an update

Juliet Compston  1
Affiliations
Review

Glucocorticoid-induced osteoporosis: an update

Juliet Compston. Endocrine. 2018 Jul.

Abstract

Glucocorticoid-induced osteoporosis is the most common secondary cause of osteoporosis and the resulting fractures cause significant morbidity. Following initiation of oral glucocorticoids, rapid bone loss occurs, and fracture risk increases within a few months in a dose-dependent manner. These adverse effects are due to inhibition of bone formation accompanied by an early but transient increase in bone resorption. Multiple mechanisms underlie these changes in bone remodeling; direct effects include upregulation of PPARγR2, increased expression of sclerostin and increased RANKL/OPG ratio, whilst hypogonadism, altered renal and intestinal calcium handling, and reduced production of insulin-like growth factor 1 also contribute. Fracture risk assessment should be performed as soon as possible after glucocorticoids are initiated and bone protective therapy started promptly in individuals at high-risk, with calcium and vitamin D supplements where appropriate. Oral bisphosphonates are currently regarded as first line options on the grounds of their low cost. However, teriparatide has been shown to be superior in its effects on BMD and vertebral fracture risk in glucocorticoid-treated individuals with osteoporosis and should be considered as an alternative first line option in high-risk patients.

Keywords: Bisphosphonates; Bone density; Fracture; Glucocorticoids; Teriparatide.

PubMed Disclaimer

Conflict of interest statement

Prof Compston has received advisory and speaking fees from Gilead and speaking fees from Amgen and UCB.

Figures

Fig. 1
Fig. 1
Direct effects of glucocorticoids on bone
See this image and copyright information in PMC

References

    1. van Staa TP, Leufkens HG, Abenhaim L, Begaud S, Zhang B, Cooper C. Use of oral corticosteroids in the United Kingdom. Q Med J. 2000;93:105–111. doi: 10.1093/qjmed/93.2.105. - DOI - PubMed
    1. Fardet L, Petersen I, Nazareth I. Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years. Rheumatology. 2011;50(11):1982–1990. doi: 10.1093/rheumatology/ker017. - DOI - PubMed
    1. Overman RA, Yeh JY, Deal CL. Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res. 2013;65(2):294–298. doi: 10.1002/acr.21796. - DOI - PubMed
    1. Silverman S, Curtis J, Saag K, Flahive J, Adachi J, Anderson F, Chapurlat R, Cooper C, Diez-Perez A, Greenspan S, Hooven F, Le Croix A, March L, Netelenbos JC, Nieves J, Pfeilschifter J, Rossini M, Roux C, Siris E, Watts N, Compston J. International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study. Osteoporos. Int. 2015;26(1):419–420. doi: 10.1007/s00198-014-2883-2. - DOI - PMC - PubMed
    1. van Staa T, Leufkens HGM, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J. Bone Miner. Res. 2000;15:933–1000. - PubMed

MeSH terms

Substances

LinkOut - more resources